November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Keith W Pratz: The utility of post remission use of GCSF in the VIALE-A trial
Nov 8, 2024, 14:30

Keith W Pratz: The utility of post remission use of GCSF in the VIALE-A trial

Keith W Pratz, Director of Leukemia, Hospital of University of Pennsylvania Philadelphia, shared his recent article on X:

“Happy to share our report on the utility of post remission use of GCSF in the VIALE-A trial.

In the CR/CRi patients given GCSF, OS was 30.8 m vs 21.1 mo and MRD neg response 51% vs 33%.

Important data to feel safe to use GCSF with blast clearance.”

The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia.

Authors: Courtney D. DiNardo, et al.

 

Keith W Pratz: The utility of post remission use of GCSF in the VIALE-A trial